Hanikoglu Ferhat, Huseyinoglu Nergiz, Ozben Serkan, Cort Aysegul, Ozdem Sebahat, Ozben Tomris
1Medical Faculty, Department of Medical Biochemistry, Akdeniz University , 07070, Antalya , Turkey.
Int J Neurosci. 2015;125(9):655-62. doi: 10.3109/00207454.2014.960521. Epub 2014 Sep 30.
PURPOSE/AIM: Obstructive sleep apnea (OSA) is characterized by recurrent respiratory disorders associated with increased cardiovascular morbidity and mortality. The increment of systemic inflammation in OSA has been considered as the major pathogenic mechanism leading to cardiovascular diseases. There is limited and conflicting information in the literature investigating myeloperoxidase (MPO) activity and soluble tumor necrosis factor receptor-1 (sTNF-R1) levels in OSA patients. The aim of our study is to assess the clinical utility of plasma MPO activity and sTNF-R1 levels as risk markers for systemic inflammation and development of cardiovascular diseases in OSA patients.
59 OSA patients diagnosed with polysomnograhpy for Apnea-Hypopnea index (AHI), and 26 healthy volunteers enrolled into the study. Plasma MPO activity was measured using a spectrophotometric method. An enzyme-linked immunosorbent assay (ELISA) method was used to detect plasma sTNF-R1 levels.
Plasma MPO activity and sTNF-R1 levels were significantly higher (43.2 ± 21.65 vs. 30.44 ± 8.05 p = .0046; 2.379 ± 1.2 vs. 1.086 ± 0.86 p < .0001, respectively) in the total OSA patients compared to the control group. There was a significant weak correlation between MPO activity and disease severity indicator AHI (p = .03 r = .27).
Elevated plasma MPO activity and sTNF-R1 levels in the OSA patients indicate increased systemic inflammation and oxidative stress which might contribute to the higher incidence of cardiovascular diseases. Therefore, we recommend measurement of plasma MPO activity and sTNF-R1 levels in the OSA patients as potential risk predictors for cardiovascular diseases.
目的/目标：阻塞性睡眠呼吸暂停（OSA）的特征是反复出现呼吸紊乱，并伴有心血管疾病发病率和死亡率的增加。OSA中全身炎症的增加被认为是导致心血管疾病的主要致病机制。关于OSA患者髓过氧化物酶（MPO）活性和可溶性肿瘤坏死因子受体-1（sTNF-R1）水平的研究，文献中的信息有限且相互矛盾。我们研究的目的是评估血浆MPO活性和sTNF-R1水平作为OSA患者全身炎症和心血管疾病发生风险标志物的临床效用。
59例经多导睡眠图诊断为呼吸暂停低通气指数（AHI）的OSA患者和26名健康志愿者纳入本研究。采用分光光度法测量血浆MPO活性。采用酶联免疫吸附测定（ELISA）法检测血浆sTNF-R1水平。
与对照组相比，OSA患者总体血浆MPO活性和sTNF-R1水平显著更高（分别为43.2±21.65对30.44±8.05，p = 0.0046；2.379±1.2对1.086±0.86，p < 0.0001）。MPO活性与疾病严重程度指标AHI之间存在显著弱相关性（p = 0.03，r = 0.27）。
OSA患者血浆MPO活性和sTNF-R1水平升高表明全身炎症和氧化应激增加，这可能导致心血管疾病发病率更高。因此，我们建议检测OSA患者血浆MPO活性和sTNF-R1水平，作为心血管疾病的潜在风险预测指标。
